Liquid Biopsy in Breast Cancer

Maggie Banys-Paluchowski; Natalia Krawczyk; Tanja Fehm

doi:10.1055/a-1467-0165

Liquid Biopsy in Breast Cancer

Translated title of the contribution: Liquid Biopsy in Breast Cancer

Maggie Banys-Paluchowski^*, Natalia Krawczyk, Tanja Fehm

^*Corresponding author for this work

Abstract

In recent years, the blood-based analysis of circulating tumour cells (CTCs) and nucleic acids (DNA/RNA), otherwise known as liquid biopsy, has become increasingly important in breast cancer. Numerous trials have already underscored the high prognostic significance of CTC detection in both early and metastatic stages. Moreover, the changes in CTC levels and circulating tumour DNA (ctDNA) during the course of the disease correlate with the response to treatment. Research currently focuses on liquid-biopsy based therapeutic interventions in metastatic breast cancer. In this context, alpelisib, a PI3K inhibitor, was the first agent to be approved by FDA and EMA.

Translated title of the contribution	Liquid Biopsy in Breast Cancer
Original language	German
Journal	Tumor Diagnostik und Therapie
Volume	42
Issue number	5
Pages (from-to)	361-372
Number of pages	12
ISSN	0722-219X
DOIs	https://doi.org/10.1055/a-1467-0165 https://doi.org/10.1055/a-1124-7225
Publication status	Published - 01.06.2021

Research Areas and Centers

Centers: University Cancer Center Schleswig-Holstein (UCCSH)
Research Area: Luebeck Integrated Oncology Network (LION)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Cite this

@article{436ebbea2fd4474cbeb09a54cbbaab28,

title = "Liquid Biopsy in Breast Cancer",

abstract = "In recent years, the blood-based analysis of circulating tumour cells (CTCs) and nucleic acids (DNA/RNA), otherwise known as liquid biopsy, has become increasingly important in breast cancer. Numerous trials have already underscored the high prognostic significance of CTC detection in both early and metastatic stages. Moreover, the changes in CTC levels and circulating tumour DNA (ctDNA) during the course of the disease correlate with the response to treatment. Research currently focuses on liquid-biopsy based therapeutic interventions in metastatic breast cancer. In this context, alpelisib, a PI3K inhibitor, was the first agent to be approved by FDA and EMA.",

author = "Maggie Banys-Paluchowski and Natalia Krawczyk and Tanja Fehm",

year = "2021",

month = jun,

day = "1",

doi = "10.1055/a-1467-0165",

language = "Deutsch",

volume = "42",

pages = "361--372",

journal = "Tumor Diagnostik und Therapie",

issn = "0722-219X",

number = "5",

}

TY - JOUR

T1 - Liquid Biopsy in Breast Cancer

AU - Banys-Paluchowski, Maggie

AU - Krawczyk, Natalia

AU - Fehm, Tanja

PY - 2021/6/1

Y1 - 2021/6/1

N2 - In recent years, the blood-based analysis of circulating tumour cells (CTCs) and nucleic acids (DNA/RNA), otherwise known as liquid biopsy, has become increasingly important in breast cancer. Numerous trials have already underscored the high prognostic significance of CTC detection in both early and metastatic stages. Moreover, the changes in CTC levels and circulating tumour DNA (ctDNA) during the course of the disease correlate with the response to treatment. Research currently focuses on liquid-biopsy based therapeutic interventions in metastatic breast cancer. In this context, alpelisib, a PI3K inhibitor, was the first agent to be approved by FDA and EMA.

AB - In recent years, the blood-based analysis of circulating tumour cells (CTCs) and nucleic acids (DNA/RNA), otherwise known as liquid biopsy, has become increasingly important in breast cancer. Numerous trials have already underscored the high prognostic significance of CTC detection in both early and metastatic stages. Moreover, the changes in CTC levels and circulating tumour DNA (ctDNA) during the course of the disease correlate with the response to treatment. Research currently focuses on liquid-biopsy based therapeutic interventions in metastatic breast cancer. In this context, alpelisib, a PI3K inhibitor, was the first agent to be approved by FDA and EMA.

UR - http://www.scopus.com/inward/record.url?scp=85107302137&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/2d38eb04-7cec-3e1b-b4c4-14f1e8b1d4bc/

U2 - 10.1055/a-1467-0165

DO - 10.1055/a-1467-0165

M3 - Zeitschriftenaufsätze

AN - SCOPUS:85107302137

SN - 0722-219X

VL - 42

SP - 361

EP - 372

JO - Tumor Diagnostik und Therapie

JF - Tumor Diagnostik und Therapie

IS - 5

ER -

Liquid Biopsy in Breast Cancer

Abstract

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this